ScinoPharm Taiwan (台灣神隆), which supplies active pharmaceutical ingredients, reported a profit decline of 37.82 percent last quarter from a quarter ago because of lower gross margin from its product mix.
The company posted a profit of NT$252.5 million (US$8.56 million), down from NT$406.08 million in the second quarter, according to the company’s filing to the Taiwan Stock Exchange.
That figure was 22.43 percent lower than NT$325.5 million the previous year, the filing said.
“Because we deliver our products on a made-to-order basis, the products we sell within a period are determined by the orders of our clients, and the product-mix we had last quarter happened to generate a lower profit margin,” ScinoPharm chief financial officer Patricia Chou (周珮芬) said at an investors’ conference yesterday.
Last quarter, gross margin declined to 42.75 percent from 54.11 percent the previous quarter and 49.86 percent a year ago, the filing said.
Chou said that the company’s products this quarter will have higher gross margin than those in the last quarter, and in the long term the company is likely to keep its gross margin between 45 percent and 50 percent.
From January through September, the company registered a profit of NT$1 billion, or NT$1.49 per share, up 35 percent from NT$748 million a year ago.
During the nine-month period, gross margin was 51 percent, up from 50 percent the previous year, the filing said.
The firm’s factory in Changshu, China, which can produce 250 cubic meters of active pharmaceutical ingredients a year, is expected to be operational by the middle of next year if the Chinese government completes the validation process within three to six months, ScinoPharm president and chief executive Jo Shen (馬海怡) said, adding that the new factory can help the firm increase sales in China.
Eyeing the rising competition of active pharmaceutical ingredients from companies in India and China, ScinoPharm is also building a factory to make formulation in Greater Tainan, Shen said, adding that the factory’s first production line is to start operating next year.
“We will strive to post higher growth than that of the global active pharmaceutical ingredient sector,” she said.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by